VITAMIST® Unveils New Enhanced Website for Premium Vitamin Oral Sprays

VITAMIST®, inventor of vitamin oral sprays, is excited to announce the launch of its newly redesigned website, www.vitamist.com. This significant update underscores VITAMIST's commitment to providing high-quality, science-backed vitamin solutions. - June 13, 2024 - VitaMist

Cayman Chemical Expands Molecular Diagnostic Research Offerings Through Partnership with PCRassays.com

Cayman Chemical, a leading supplier of research tools for the life science community, has widened their portfolio to include molecular-based detection kits through a strategic partnership with PCRassays.com. PCRassays.com offers more than 200 qPCR-based assays for infectious diseases, over 50 of... - June 07, 2024 - Cayman Chemical Company

Jusha International and Dextro Imaging Form Strategic Partnership

Jusha International and Dextro Imaging Form Strategic Partnership

Jusha International Collaborates with Dextro Imaging Specialists, Revolutionizing Radiology with Lower Costs and Enhanced Quality - May 28, 2024 - Dextro

GENINVO Launches Its Latest Offering – DocWrightAI

GENINVO, a leading provider of life science products and business solutions announced the launch of its new, on-demand service: DocWrightAI. GENINVO understands the various challenges in generating clinical documents. The time taken to draft clinical documents with accuracy and compliance has... - May 18, 2024 - GenInvo, Inc.

Snova's Halal Extract Wins Its Third Consecutive Gold at the Monde Selection

Snova's Halal Extract Wins Its Third Consecutive Gold at the Monde Selection

Snova’s Halal Extract has won the gold award for its third consecutive year at the Monde Selection 2024. ・Snova’s Halal Extract is a skincare product manufactured in accordance with Islamic law (Halal). In Islam, certain ingredients and manufacturing processes are prohibited, so... - May 15, 2024 - Snova Co.

Dr. Pompa Explores the Hidden Risks of Root Canals

Dr. Pompa discusses the hidden risks of root canals in his latest health coaching initiative, revealing that often these procedures may carry infections that affect surrounding tissues. Despite meticulous care, root canals inherently possess risks, suggesting that sometimes avoiding the procedure might be safer. This exploration underscores the importance of careful decision-making and consultation in dental health and wellness. - May 10, 2024 - Pompa Program

SeabuckWonders Unveils Functional New Product for Women

SeabuckWonders Unveils Functional New Product for Women

Fem-Omega 7 Makes its Debut as Ultimate Supplement for Female Dryness. - May 08, 2024 - SeabuckWonders

Novugen Launches Pazopanib Tablets, 200mg, in the U.S. Following ANDA Approval by USFDA

Novugen Launches Pazopanib Tablets, 200mg, in the U.S. Following ANDA Approval by USFDA

Novugen has launched Pazopanib tablets, 200mg, in the U.S. after receiving ANDA approval from USFDA on April 23, 2024. This significant milestone demonstrates Novugen's continued growth in the U.S. pharmaceutical market with a complex anticancer drug, the generic equivalent of Votrient, used to treat advanced renal cell carcinoma (RCC) and advanced soft tissue sarcoma (STS). - May 07, 2024 - Novugen

Pagari Life Science Corp. Announces the Commercial Launch of Helocaine®, a New Transformative Cold Sore Treatment

Pagari Life Science Corp. Announces the Commercial Launch of Helocaine®, a New Transformative Cold Sore Treatment

Pagari Life Science Corporation is revolutionizing cold sore treatment with the commercial launch of Helocaine®. - May 01, 2024 - Pagari Life Sciences

Revolutionizing Clinical Trials: AnzuBridge Unveils Next-Generation Solutions for Improved Efficacy Evaluations in the Treatment of Rare Disease

Revolutionizing Clinical Trials: AnzuBridge Unveils Next-Generation Solutions for Improved Efficacy Evaluations in the Treatment of Rare Disease

AnzuBridge® updates its CDMS to enhance biotech evaluations with advanced video tools, ensuring precise efficacy recording and compliance. It supports scalable trials and features HIPAA-compliant media capture, ePRO for patient engagement, and sophisticated video review capabilities, all integrated with a Learning Management System for efficient trial management. - April 30, 2024 - Anzu

No More Acetone: Thar Process Develops Clean and Green Process to Create Sterile, Fat-Free Lecithin Powder and GMP Quality Oils for Human Consumption

No More Acetone: Thar Process Develops Clean and Green Process to Create Sterile, Fat-Free Lecithin Powder and GMP Quality Oils for Human Consumption

Thar Process, with 34 years of expertise in supercritical fluid extraction, has developed a sustainable way to produce de-fatted lecithin powder that has less oil and longer shelf-life stability. The new process is semi-continuous and sustainable because it utilizes upcycled CO2 from waste sources instead of using toxic acetone which is the industry standard. - April 26, 2024 - Thar Process, LLC

Revvity’s EUROIMMUN and ALPCO-GeneProof Announce Strategic Partnership to Expand CE-IVD Molecular Assay Offerings

Revvity’s EUROIMMUN and ALPCO-GeneProof Announce Strategic Partnership to Expand CE-IVD Molecular Assay Offerings

Revvity’s EUROIMMUN business, a leading provider of high-quality in-vitro diagnostic products, and ALPCO-GeneProof, a global leader in molecular diagnostics, jointly announced a strategic partnership to enhance the availability of GeneProof PCR kits throughout the European Union. This... - April 25, 2024 - ALPCO

Mirror Biologics, Inc. Appoints Elizabeth Czerepak as Chief Financial Officer and VP Corporate Development

Mirror Biologics, Inc. Appoints Elizabeth Czerepak as Chief Financial Officer and VP Corporate Development

Mirror Biologics, Inc., a clinical stage biopharmaceutical company announces the appointment of Elizabeth Adkins Czerepak as Chief Financial Officer (CFO) and Vice President of Corporate Development effective April 15, 2024. Ms. Czerepak has served as CFO of several biotechnology companies over... - April 18, 2024 - Mirror Biologics, Inc.

I Holland Unveils TSAR 2: Advancing Predictive Modelling in Tablet Compression

I Holland proudly announces the development of TSAR 2, an advanced predictive model developed through a collaborative partnership between academia and industry. Building upon the success of the Tabletting Science Anti-Stick Research (TSAR) project, I Holland continues its groundbreaking research... - April 12, 2024 - I Holland Ltd.

Boiron’s New Arnicare® Wellness Kits Offer Holistic Approach to Pain Management

Boiron, world leader in homeopathic medicines, introduces its new Arnicare Wellness Kits as convenient and comprehensive solutions for painsleep and stress relief. The kits are designed to provide individuals with daytime and nighttime options to manage pain with occasional sleeplessness and... - April 11, 2024 - Boiron

Huntington Study Group Launches Project AWARE 2.0 Observational Study

Huntington Study Group Launches Project AWARE 2.0 Observational Study

The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) are pleased to announce the launch of Project AWARE 2.0, an observational study developed in collaboration with Roche Products Limited and Genentech to understand and improve Awareness, Willingness, and... - April 10, 2024 - Huntington Study Group

Minus K Congratulates to the Winners of Their 2023/2024 Educational Giveaway

Minus K congratulates the four winners of the Minus K's 2023/2024 Educational Giveaway. Over $75,000 of new passive mechanical hub hertz vibration isolators have been granted to universities and colleges in the U.S. over the last ten years. - April 10, 2024 - Minus K Technology Inc.

FuseBio Presents New Data at AACR: Targeting a Functionally-Selective IL-18 (F-18) to PD-1: A Next Generation Checkpoint Inhibitor with Enhanced Anti-Tumor Activity

FuseBio's unique attenuation mechanism renders IL-18, a functionally selective IL-18, resistant to IL-18BP and 1 million percent less active in circulation and yet still retain nearly full activity when targeted to PD-1+/IL-18R+ cells, the key functional immune cells in tumors. It is designed to retain full activity of PD-1 checkpoint blockade and simultaneously deliver a functionally selective IL-18 (F-18) to preserve and enhance the anti-tumor activity of immune cells. - April 09, 2024 - Fuse Biotherapeutics

Renowned Advocate Lorrinda Gray-Davis to Speak at TRIO's Remember & Rejoice Event

Renowned Advocate Lorrinda Gray-Davis to Speak at TRIO's Remember & Rejoice Event

As a guest speaker, Lorrinda Gray-Davis will share her personal journey of hope, resilience, and gratitude, highlighting the profound impact of organ donation on individuals, families, and communities. "Remember & Rejoice" stands as the single largest gathering of donor families and transplant recipients in the country, providing a sacred space for reflection, remembrance, and rejoicing. - April 06, 2024 - TRIO-Oklahoma

Ngram Expands AI Dataset Offerings with Descriptive Question Answering for Healthcare

Ngram Expands AI Dataset Offerings with Descriptive Question Answering for Healthcare

New open-source medchat-qa-descriptive dataset enables AI models to provide comprehensive answers to complex medical queries. - March 22, 2024 - ngram Inc.

Parvus Announces Collaboration with AbbVie to Develop IBD Therapies Based on the Parvus Navacim Platform Technology

The collaboration will combine AbbVie’s expertise in Immunology with Parvus’ innovative Navacim™ regulatory T cells (Treg) immune tolerization platform technology to develop therapies for Inflammatory Bowel Disease Parvus Therapeutics announced today that it has entered into an... - March 20, 2024 - Parvus Therapeutics U.S., Inc.

AMD Stopper, a New Treatment for Age-Related Macular Degeneration, Seeks Partnerships with Manufacturers in the Healthcare Industry

AMD Stopper, a New Treatment for Age-Related Macular Degeneration, Seeks Partnerships with Manufacturers in the Healthcare Industry

California inventor of oral treatment for Age-Related Macular Degeneration, a common eye disease which affects tens of millions globally, is working tirelessly to bring his formulation to market. - March 20, 2024 - AMD Stopper

ACL Digital and PhoenixAI.tech Partner to Take AI-Driven Drone Technology to New Heights

The strategic partnership enhances ACL Digital’s capabilities with PhoenixAI.tech, focusing on AI drone solutions for UAVs, IoT, and edge computing to revolutionize operations significantly Beyond Visual Line of Sight (BVLOS) missions. - March 16, 2024 - ACL Digital

iView Therapeutics Inc. Announced FDA’s Clearance of IND Application for IVW-1001 Ophthalmic Eyelid Wipe to Treat Signs and Symptoms of Dry Eye Disease

iView Therapeutics Inc. Announced FDA’s Clearance of IND Application for IVW-1001 Ophthalmic Eyelid Wipe to Treat Signs and Symptoms of Dry Eye Disease

iView Therapeutics Inc., a clinical stage biotechnology company dedicated to advancing innovative treatments for ocular diseases, announces that the U.S. Food and Drug Administration (FDA) cleared iView’s Investigational New Drug (IND) application to for the initiation of a Phase 1/2 clinical... - March 11, 2024 - iView Therapeutics Inc.

Defined Bioscience Introduces Ready-CEPT™: A New Cell Viability Enhancer

Defined Bioscience is pleased to announce the launch of Ready-CEPT™ 1000X, a new product designed to improve stem cell survival, growth, and health during critical processes such as routine passaging, cryopreservation, and freeze-thaw recovery. - March 11, 2024 - Defined Bioscience Inc.

Utech Products Inc. Achieves ISO 9001

Utech Products Inc. Achieves ISO 9001 Certification (Certification Registration No. 961 24 5889), Demonstrating Commitment to Quality and Customer Satisfaction. - March 09, 2024 - Utech Products Inc.

IVIEW Announces Presentation of Positive Topline Results in Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis at ARVO 2024

IVIEW Announces Presentation of Positive Topline Results in Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis at ARVO 2024

IVIEW Therapeutics Inc. announces to present the positive topline result in the Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis in the upcoming 2024 ARVO (The Association for Research in Vision and Ophthalmology) national meeting in Seattle, WA. The Presentation... - February 28, 2024 - iView Therapeutics Inc.

Cayman Chemical Introduces LipidLaunch™, Expands Portfolio of Lipid Nanoparticle Research Tools to Support Advances in RNA Therapies

Cayman Chemical introduces the latest addition to the company’s portfolio of lipid nanoparticle (LNP) research tools for academic, pharma, and biotech researchers worldwide. The LipidLaunch™ product line helps researchers pursue LNPs for the delivery of nucleic acid therapies in untold health applications, ranging from vaccine development to cancer and cell or gene therapies. - February 22, 2024 - Cayman Chemical Company

Gotham Biotech’s Histoplasma Urinary Antigen EIA Kit Now Available for Purchase as Histoplasma Spreads in the U.S.

Gotham Biotech’s Histoplasma Urinary Antigen EIA Kit Now Available for Purchase as Histoplasma Spreads in the U.S.

Histoplasmosis is a systemic disease caused by the thermally dimorphic fungus Histoplasma capsulatum. H. capsulatum is distributed worldwide and endemic to the Ohio and Mississippi River Valleys, where the CDC estimates 60% to 90% of people who live in the region have been exposed to the fungus at some point during their life, and to certain regions of Central and South America. Medicare records from 2007 to 2016 have found cases of histoplasmosis have now spread to 47 states and Washington, DC. - February 15, 2024 - Gotham Biotech

GENINVO, a Leading Provider of Life Science Product and Business Solutions Announced the Offering of Its On-Demand Service/Tool: ApoGI™

ApoGI™ is an integrated, one stop automation platform that leverages Artificial Intelligence and Machine Learning algorithms to focus on standards and metadata driven generation of artifacts. The Primary objective of this platform is to help SMEs (Subject matter experts) focus on curating... - February 15, 2024 - GenInvo, Inc.

NAD3® Supplement Study: Memphis Health Sciences College Discovers Key to Cellular Rejuvenation

NAD3® Supplement Study: Memphis Health Sciences College Discovers Key to Cellular Rejuvenation

In a groundbreaking development, the College of Health Sciences at the University of Memphis, spearheaded by leading researchers Janine Hellenbrand, Richard J. Bloomer, and Marie Van der Merwe, has revealed the remarkable effects of NAD3® supplementation on adult stem cell circulation in... - February 14, 2024 - High Performance Nutrition

Biopharmaceutical Sponsor Interaction with Clinical Site Networks Pulse Report

Sponsor Outsourcing Dollars May Shift to Clinical Site Networks, Transforming the CRO Relationship - February 13, 2024 - Life Science Strategy Group, LLC

Microvascular Therapeutics Welcomes Thom Tulip as Chief Business Officer

Microvascular Therapeutics Inc. (MVT), a clinical-stage biotech company at the forefront of developing the next generation of microbubbles unlocking the therapeutic potential of ultrasound, proudly announces the appointment of Dr Thom Tulip as their new Chief Business Officer. In this pivotal role, Dr Tulip will lead capital raises to propel MVT's cutting-edge technologies into the market. - February 10, 2024 - Microvascular Therapeutics, Inc.

Flow Circuits and Rapid Fluidics Ltd. Announce Partnership to Drive Microfluidic Innovation

Flow Circuits design platform and Rapid Fluidics 3D Print capabilities perfectly complement each other for rapid fluidic system development. Combined they empower researchers in diverse markets such as Pharmaceutical & Life Sciences Research, Point of Care Testing and Clinical Diagnostics, and Environment and Industrial Analytics. - February 05, 2024 - Rapid Fluidics Ltd

Accelerating Drug Discovery: Life Science and IT Leaders Explore the Power of Artificial Intelligence April 15-17 in Boston

AI to Take Center Stage at Bio-IT World Conference & Expo, the Hub for Pharmaceutical, Biotech and IT Collaboration - February 04, 2024 - Cambridge Healthtech Institute

Patient Experience and Satisfaction with Electronic Consent, Onboarding, and Diaries in Clinical Trials Report

New Market Research Shows Different Patient Preferences for Electronic Diaries - January 31, 2024 - Life Science Strategy Group, LLC

New Sustainable Lyophilization Technology Uses Supercritical CO2

The Thar group of companies have been using CO2 for extraction, purification, particle design and encapsulation for many years but recent developments point to a need for sustainable methods for drying APIs, intermediates, excipients and biologics at relatively low temperatures. 'Big Pharma' has depended on Thar for SFC tools in drug discovery but lyophilization will likely be used in manufacturing too. - January 28, 2024 - Thar Process, LLC

Huntington Study Group Announces 2024 Annual Meeting

Huntington Study Group Announces 2024 Annual Meeting

The Huntington Study Group® (HSG), together with its wholly owned subsidiary, HSG Clinical Research, Inc., a world leader in conducting clinical trials for Huntington’s disease (HD), is pleased to announce that its annual meeting for 2024 is slated to take place from November 6-9 at the... - January 22, 2024 - Huntington Study Group

Johari Digital Healthcare Limited Hosts Successful Webinar on Design for Manufacturing (DFM) for Medical Devices

Johari Digital Healthcare hosted a successful webinar on "Building Cost-effective Medical Devices through Design for Manufacturing." The 60-minute event discussed challenges in balancing cost and product robustness, featuring real-world case studies. Speakers highlighted early DFM benefits, such as cost reduction and faster time-to-market. - January 22, 2024 - Johari Digital Healthcare Ltd.

Impact of the In Vitro Diagnostic Regulation on Clinical Trials in the EU and CRO Outsourcing Report

IVDR Delays Driving Trial Sponsors to Actively Seek Alternative Site and CRO Outsourcing Strategies - January 17, 2024 - Life Science Strategy Group, LLC

New Ultra-Thin, Compact Low-Height, Low-Frequency Vibration Isolation Platform Adapts to Space Constraints in Critical Micro- and Nano-Microscopy

At about 2-1/2 inches in height, while isolating vibrations as low as 1 hertz, the new completely-passive Negative-Stiffness tabletop vibration isolation platform – developed by Minus K Technology – provides the industry’s thinnest low-height, low-frequency isolator for Microscopy (SPM, SEM, AFM, etc.), Micro-Hardness and Nano-Indenter Testing, Laser/Optical Systems, Biology/Neuroscience Systems, Spacecraft Ground Testing, Analytical Balances, Audio Reproduction, Vacuum & Cleanroom applications. - January 10, 2024 - Minus K Technology Inc.

ALPCO Announces the Commercial Launch of Its FDA 510(K) Cleared Calprotectin Immunoturbidimetric Assay

American Laboratory Products Company, Ltd. ("ALPCO"), a global provider of specialty diagnostic solutions, proudly announces the commercial launch of its FDA 510(k) cleared Calprotectin Immunoturbidimetric Assay, enhancing its suite of Gastrointestinal (GI) diagnostic solutions. In July... - December 19, 2023 - ALPCO

Johari Digital Healthcare Ltd. Clinches Prestigious "Pharmaceutical & Healthcare MSME of the Year" Award at ET MSME Awards 2023

Johari Digital Healthcare Ltd. has clinched the esteemed "Pharmaceutical & Healthcare MSME of the Year" award at the ET MSME Awards 2023 in New Delhi. Celebrating the resilience of India's MSME sector, the event recognized Johari Digital Healthcare Ltd. for its exceptional contributions to healthcare, particularly in manufacturing and research & development. - December 18, 2023 - Johari Digital Healthcare Ltd.

Empowering Data Privacy: GENINVO Offers Anonymization as a Service

GENINVO, a leading provider of life science product and business solutions announced the offering of its on-demand service Anonymization as a Service. GENINVO a trailblazer in data privacy solutions, is excited to introduce its ground-breaking offering, Anonymization as a Service. With data... - December 14, 2023 - GenInvo, Inc.

Huntington Study Group and Roche Collaborate on GENERATION HD2 Study

Huntington Study Group and Roche Collaborate on GENERATION HD2 Study

The Huntington Study Group together with its wholly-owned clinical research organization, HSG Clinical Research, Inc. (HSGCR), is pleased to announce a collaboration with Roche-Genentech to optimize our collective experiences in Huntington’s disease (HD) clinical research. Together we are... - December 13, 2023 - Huntington Study Group

Breakthrough Study by Microvascular Therapeutics Reveals Fibrin-Targeted Phase Shift Microbubbles as Promising Solution for Microvascular Obstruction

Microvascular Therapeutics, a trailblazing healthcare research and development company, announces a groundbreaking study on the treatment of Microvascular Obstruction (MVO) through sonoreperfusion. The study, led by Dr. John J. Pacella and his team at the Center for Ultrasound Molecular Imaging and... - December 13, 2023 - Microvascular Therapeutics, Inc.

Microvascular Therapeutics Selected as a Participant in the 2023 H7 BioCapital Accelerator Program

Microvascular Therapeutics (MVT), a clinical stage biopharma pioneering the potential of ultrasound in diagnostics and theranostics, has been selected to join the prestigious H7 Healthcare Accelerator 2023 Cohort, powered by H7 BioCapital. The program is renowned for providing a dynamic platform... - December 13, 2023 - Microvascular Therapeutics, Inc.

Herb Llama Launches Plant-Based, Adaptogenic Superfood Supplements: a Revolution in Modern Holistic Wellness

Herb Llama Launches Plant-Based, Adaptogenic Superfood Supplements: a Revolution in Modern Holistic Wellness

Herb Llama, an American wellness company, has launched a new range of adaptogenic, plant-based superfood supplements targeting health-conscious adults. The company, driven by the motto "vitamins as nature intended," ensures its plant-based products align with modern holistic wellness. - November 30, 2023 - Herb Llama

Huntington Study Group® Holds 30th Annual Meeting

Huntington Study Group® Holds 30th Annual Meeting

The Huntington Study Group® (HSG®), a world leader in conducting clinical trials and providing educational programming for Huntington’s disease (HD), recently held its 30th annual meeting, HSG 2023, November 2-4 in Phoenix, AZ. Hundreds of scientists, industry partners, HSG research... - November 21, 2023 - Huntington Study Group

Performance Inspired Nutrition Partners with Delta Common to Sell PI Products Throughout India

This new partnership offers an exciting opportunity for PI to introduce its clean and natural products to millions. - November 17, 2023 - Performance Inspired Nutrition

Press Releases 1 - 50 of 3,128